Status:
COMPLETED
Iressa Follow-up Trial
Lead Sponsor:
AstraZeneca
Conditions:
Lung Cancer
Breast Cancer
Eligibility:
All Genders
18-99 years
Phase:
PHASE3
Brief Summary
The purpose of this study is to assess the long-term safety profile and the secondary objective to estimate clinical benefit of ZD1839 (gefitinib).
Eligibility Criteria
Inclusion
- Provision of written informed consent to participate in the trial.
- Female or male aged 18 years and over.
- Patients with previously diagnosed cancer who have been treated with ZD1839 in a parent ZD1839 clinical trial and may benefit from continuation
Exclusion
- Known severe hypersensitivity to ZD1839
- Concomitant use of phenytoin, carbamazepine, rifampicin, barbiturates, or St John's Wort.
- Withdrawal from a parent ZD1839 trial because of tumor progress
Key Trial Info
Start Date :
January 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 1 2015
Estimated Enrollment :
14 Patients enrolled
Trial Details
Trial ID
NCT00357734
Start Date
January 1 2005
End Date
May 1 2015
Last Update
August 30 2016
Active Locations (7)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Freiburg im Breisgau, Germany
2
Research Site
Gauting, Germany
3
Research Site
Großhansdorf, Germany
4
Research Site
Hemer, Germany